Drug Profile
GDC 0349
Alternative Names: GDC0349; RG-7603Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genentech
- Class Antineoplastics; Small molecules
- Mechanism of Action MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma in Canada (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma in USA (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in Canada (PO)